Exosomes · Lesson 17 of 18 · 2 min

Personalized exosome therapy: why responses vary and what biomarkers could add

Why response to exosomes appears to vary between individuals, how disease stage may matter, and what predictive biomarkers are meant to do.

A gloved hand pipetting into small vials on a lab bench

Key takeaways.

  • Response to exosome therapy appears to vary widely, though clinical data are limited.
  • Reports describe a spread from marked improvement to no detectable benefit.
  • Disease stage is the most obvious candidate factor, with earlier disease the more plausible setting.
  • Predictive biomarkers are pre-treatment measurements that forecast the likelihood of response.
  • Predictive biomarkers differ from prognostic and pharmacodynamic biomarkers.
  • Exosomes are not FDA-approved for therapeutic use, and personalization is still a research goal.

Responses appear to vary

Precision medicine means tailoring treatment to the individual instead of applying one protocol to everyone. It is most advanced in oncology and is now being discussed for biologics.

For exosomes, the picture comes from case series, pilot trial reports and anecdotal experience, so it is not well characterized. The reported pattern resembles other biologics. Some individuals are described as improving markedly, a larger group moderately, and others little or not at all.

Why disease stage may matter

Disease stage is the most obvious candidate explanation. The biological reasoning is that the proposed mechanisms need target cells that can still respond.

In osteoarthritis, for example, early disease with preserved cartilage is thought to be a more plausible setting than end-stage disease where cartilage is gone. This is a rationale, not a demonstrated result.

What predictive biomarkers are for

A predictive biomarker is a measurement taken before treatment that forecasts how likely an individual is to respond. In trials, such markers could enrich for likely responders and spare others unnecessary exposure.

Two related terms mean different things. A prognostic biomarker predicts the course of disease regardless of treatment. A pharmacodynamic biomarker shows that a treatment engaged its target, without necessarily predicting benefit.

Where this stands

Personalization of exosome therapy is a research direction, not current practice. Validated predictive biomarkers would require far more clinical data than exist today.

Exosome therapies are not FDA-approved for therapeutic use.

Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.

Exosomes: 0 of 18 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • Autologous versus allogeneic approaches
  • Biomarker-guided selection strategies
  • Exosome engineering for targeted delivery
  • Applying precision medicine principles in practice

Common questions.

Why do some patients respond to exosomes and others do not?
This is not established. Disease stage is the most obvious candidate factor, but response variation has not been well characterized because clinical data are limited.
What is a predictive biomarker?
It is a measurement taken before treatment that forecasts an individual's likelihood of responding. It differs from a prognostic biomarker, which predicts disease course regardless of treatment.

Sources

  • Murphy, D. E., et al. (2019). Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Experimental & Molecular Medicine, 51, 1-12.
  • Wiklander, O. P. B., et al. (2015). Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. Journal of Extracellular Vesicles, 4, 26316.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.